• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Biocept Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOC

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Biocept in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for BIOC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Biocept. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/14/2023Maxim GroupDowngradeBuy ➝ Hold
1/6/2023Brookline Capital ManagementDowngradeBuy ➝ Hold
10/3/2022Brookline Capital ManagementReiterated RatingBuy
6/20/2022Maxim GroupSet Target$120.00
5/26/2022Maxim GroupLower Target$150.00
10/9/2021Brookline Capital AcquisitionReiterated RatingBuy
10/8/2021Brookline Capital ManagementReiterated RatingBuy
12/11/2020Maxim GroupInitiated CoverageBuy$600.00
11/13/2020Maxim GroupReiterated RatingBuy
8/13/2020Maxim GroupBoost TargetBuy$300.00 ➝ $600.00
8/4/2020Maxim GroupReiterated RatingBuy$300.00
6/23/2020Maxim GroupReiterated RatingBuy$300.00
6/1/2020Maxim GroupInitiated CoverageBuy$300.00
5/15/2020Maxim GroupInitiated CoverageBuy$300.00
5/14/2020Brookline Capital ManagementInitiated CoverageBuy
4/14/2020Maxim GroupReiterated RatingBuy$300.00
3/6/2020Maxim GroupReiterated RatingBuy$300.00
1/8/2020Maxim GroupReiterated RatingBuy$300.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Biocept logo
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.97
Low: $0.43
High: $1.67

52 Week Range

Now: N/A

Volume

751,400 shs

Average Volume

764,067 shs

Market Capitalization

$1.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Biocept?

The following Wall Street analysts have issued research reports on Biocept in the last year: StockNews.com.
View the latest analyst ratings for BIOC.

What is the current price target for Biocept?

0 Wall Street analysts have set twelve-month price targets for Biocept in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Biocept in the next year.
View the latest price targets for BIOC.

What is the current consensus analyst rating for Biocept?

Biocept currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BIOC.

What other companies compete with Biocept?

How do I contact Biocept's investor relations team?

Biocept's physical mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company's listed phone number is (858) 320-8200 and its investor relations email address is [email protected]. The official website for Biocept is www.biocept.com. Learn More about contacing Biocept investor relations.